Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira versus unchanged GLP-1 receptor agonist therapy in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and metformin
2012-000209-63Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing insulin degludec + liraglutide with unchanged GLP-1 receptor agonist therapy (2 arms). Primary endpoint: Change in HbA1c from baseline. Started Jul 2012; status: completed.
02
Drugs
insulin degludecliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-000209-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000209-63.